U.S. STOCKS ON THE MOVE-Chemours, Hyster-Yale, Guidewire
NASH drug developers fall after Eli Lilly's obesity drug shows liver scarring benefit
Brief: 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis Patients with Compensated Cirrhosis
Brief: 89Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: 89bio Q1 Net Income USD -51.681 Million Vs. IBES Estimate USD -41.5 Million
89Bio Inc expected to post a loss of 46 cents a share - Earnings Preview
Brief: 89bio Appoints Biotech Industry Veteran, Martin Babler To Its Board Of Directors
Brief: 89Bio Inc Enters Into Collaboration Agreement With Bibo Biopharma Engineering Co Ltd
Brief: 89bio Receives EMA PRIME Status For Pegozafermin In Treatment Of MASH With Fibrosis, Compensated Cirrhosis
Madrigal jumps on FDA approval for fatty liver disease drug
Factbox: Madrigal's drug wins first US approval for fatty liver disease NASH as rivals circle
Brief: 89bio Q4 Net Income USD -40.235 Million Vs. IBES Estimate USD -39 Million
U.S. STOCKS ON THE MOVE-Adobe, United Parcel Service, ZeroFox Holdings
Nash Drug Developers Fall As Lilly's Weight: loss drug shows promise in trial
U.S. STOCKS ON THE MOVE-New York Community Bancorp, Rallybio, Willis Towers Watson
U.S. STOCKS ON THE MOVE-DocuSign, Eli Lilly, Sunworks
NASH drug developers fall as Lilly's drug shows promise in trial
U.S. STOCKS ON THE MOVE-Boeing, Regeneron, Defense stocks
U.S. STOCKS ON THE MOVE-Polestar Automotive, Momentus, oil firms